IRMDHealthcare · Medical DevicesThe 2 Wall Street analysts covering IRadimed Corp. hold a median 12-month price target of $118 — +43.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 89 of 100 as at 19 Sept 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores IRadimed Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (100): The share price has been relatively steady.
Accruals (38): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on IRMD, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +43.1% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 2 Apr 2026 | Freedom Broker | Initiates | Buy | $116 |
| 2 Apr 2026 | Freedom Broker | Initiates | Buy | — |
| 14 Feb 2025 | Roth MKM | Reiterates | Buy | — |
| 2 Aug 2024 | Roth MKM | Maintains | Buy | — |
| 22 Apr 2024 | Roth MKM | Reinstates | Buy | $65 |
| 2 Aug 2021 | Roth Capital | Maintains | Buy | — |
| 31 July 2017 | Roth Capital | Upgrade | Buy | — |
| 5 Oct 2016 | Roth Capital | Downgrade | Neutral | — |
| 4 Apr 2016 | Roth Capital | Maintains | Buy | — |
| 16 June 2015 | Roth Capital | Maintains | Buy | — |
| 11 Aug 2014 | Roth Capital | Initiates | — | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. IRMD appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 21 Sept 2026, IRadimed Corp. returned +18.6% against +17.8% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 15% of US stocks
Cheaper than 13% of US stocks
Cheaper than 9% of US stocks
Cheaper than 8% of US stocks
Higher than 28% of US stocks
Higher than 27% of US stocks
Higher than 86% of US stocks
Higher than 88% of US stocks
Higher than 87% of US stocks
Higher than 84% of US stocks
Higher than 97% of US stocks
Higher than 21% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
IRadimed Corp. has a market value of $1.1B and an enterprise value of $991.0M.
Revenue in the twelve months to 30 June 2026: $86.3M. The latest quarter grew 0.3% year on year.
Net income over the same four quarters: $23.1M, a 26.7% net margin.
Diluted earnings per share, trailing twelve months: $1.79.
Free cash flow in the twelve months to 30 June 2026: $24.5M, after $572K of capital spending.
IRadimed Corp. spent $15.8M on dividends in the twelve months to 30 June 2026.
Trailing P/E: 45.9×; forward P/E: 34.1× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.98%, paying out 41% of earnings.
IRadimed Corp. employs 166 people — $520K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own IRadimed Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
iRadimed reported second-quarter 2026 revenue of $20.5 million, up 0.5% year-over-year, and began general-release production of its new 3870 MRI IV pump system while managing initial manufacturing ramp costs.
Why it matters — The update signals iRadimed's progress in launching the new 3870 MRI IV pump system, a key product for the company, while navigating the costs tied to ramping up production.
IRADIMED Corporation held its Q2 2026 earnings call, and a transcript of the call was published on Seeking Alpha.
Why it matters — IRMD watchers would care because earnings call transcripts provide direct insight into management's commentary on the company's quarterly performance and outlook.
IRADIMED CORPORATION reported second-quarter 2026 revenue of $20.5 million, a 0.5% increase over the same period in 2025. The company announced a regular quarterly cash dividend of $0.20 per share, reported GAAP diluted EPS of $0.41 and non-GAAP diluted EPS of $0.46, and reaffirmed its full-year 2026 revenue and earnings guidance.
Why it matters — IRMD watchers would care because the results show modest revenue growth and an ongoing dividend payout, while the reaffirmed guidance signals that management expects full-year performance to remain on track.
IRADIMED CORPORATION announced it will release its second quarter 2026 financial results before market open on July 31, 2026, and will host a conference call at 11:00 a.m. Eastern Time that day to discuss the results with investors.
Why it matters — The conference call gives IRMD shareholders and analysts an opportunity to hear management's discussion of the company's quarterly performance and ask questions directly.
The 2 Wall Street analysts covering IRadimed Corp. have a median 12-month price target of $118, with estimates ranging from $116 to $120. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 2 analysts covering IRadimed Corp., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks IRadimed Corp. 89 out of 100 across roughly 4,600 US stocks as at 19 Sept 2026. None of this is personal advice — it does not consider your circumstances.
As at 19 Sept 2026, IRadimed Corp. ranks 89 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (100 of 100).
No one can know that. What the data says: the median 12-month target from 2 analysts implies +43.1% from the last close, and Ticker Nerd's factor model ranks IRadimed Corp. 89 out of 100 as at 19 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering IRadimed Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for IRMD are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $116 to $120 over the next 12 months.
IRadimed Corp. returned +18.6% over the 12 months to 21 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
iRadimed Corporation is a medical device company that develops, manufactures, markets, and distributes MRI-compatible patient care solutions. Its product portfolio includes MRI-compatible intravenous infusion pump systems, patient vital signs monitoring systems, ferromagnetic detection devices, and related accessories and disposables designed for use in magnetic resonance imaging environments.
The most recent item we track (MarketBeat, 31 July 2026): "iRadimed Q2 Earnings Call Highlights". iRadimed reported second-quarter 2026 revenue of $20.5 million, up 0.5% year-over-year, and began general-release production of its new 3870 MRI IV pump system while managing initial manufacturing ramp costs.
iRadimed Corporation is a medical device company that develops, manufactures, markets, and distributes MRI-compatible patient care solutions. Its product portfolio includes MRI-compatible intravenous infusion pump systems, patient vital signs monitoring systems, ferromagnetic detection devices, and related accessories and disposables designed for use in magnetic resonance imaging environments. The company’s products are used by hospitals, acute care facilities, and outpatient imaging centers to support patient monitoring and medication delivery during MRI procedures. iRadimed Corporation focuses on equipment engineered with non-magnetic components to help maintain clinical workflow and patient safety in high-field imaging settings. Headquartered in Orlando, Florida, iRadimed Corporation serves customers in the United States and internationally through a specialized medical technology platform centered on MRI-compatible care.
CEO Mr. Roger E. Susi · 166 employees · United States · https://www.iradimed.com
